rotein tyrosine kinases (tk s ) are enzymes that catalyze the transfer of phosphate from ATP to tyrosine residues in polypeptides. The human genome contains about 90 TK and 43 TK-like genes, the products of which regulate cellular proliferation, survival, differentiation, function, and motility. More than 25 years ago, TKs were implicated as oncogenes in animal tumors induced by retroviruses. However, they were largely ignored in drug development because of a paucity of evidence for a causative role in human cancer and concerns about drug specificity and toxicity. The landscape was changed radically by the success of imatinib mesylate, an inhibitor of the BCR-ABL TK in chronic myeloid leukemia (CML) -a result heralded as a proof-of-principle and a triumph of targeted cancer therapy. TKs are now regarded as excellent targets for cancer chemotherapy, but reality lies somewhere between the extremes of triumph and tribulation. In this article we will review mechanisms of aberrant TK signaling and strategies to inhibit TKs in cancer, summarize the status of TK-directed cancer therapies, and discuss challenges and prospects for the future.
regulation of normal tk activity
TKs are divided into two main classes (Fig. 1) . Receptor TKs are transmembrane proteins with a ligand-binding extracellular domain and a catalytic intracellular kinase domain, whereas nonreceptor TKs lack transmembrane domains and are found in the cytosol, the nucleus, and the inner surface of the plasma membrane. The enzymatic activities of both types of TK are under tight control, so that nonproliferating cells have very low levels of tyrosyl phosphorylated proteins. The kinase domains of all TKs have a bilobar structure, with an N-terminal lobe that binds ATP and magnesium, a C-terminal lobe containing an activation loop, and a cleft between the lobes to which polypeptide substrates bind.
In the absence of ligand, receptor TKs are unphosphorylated and monomeric, and the conformation of their kinase domains is inactive. In some receptor TKs, the cytoplasmic juxtamembrane region further inhibits the enzyme by interacting with the kinase domain. 2 Receptor TKs become activated when ligand binds to the extracellular domain, resulting in receptor oligomerization, disruption of the autoinhibitory juxtamembrane interaction, and autophosphorylation of a regulatory tyrosine within the activation loop of the kinase (Fig. 1 ). These changes reorient critical amino acid residues, thereby increasing the catalytic activity of the enzyme. After activation, autophosphorylation generates binding sites for signaling proteins, recruiting them to the membrane and activating multiple signaling pathways. 3 The nonreceptor TKs, typified by c-ABL, are maintained in an inactive state by cellular inhibitor proteins and lipids and through intramolecular autoinhibition. 1 Nonreceptor TKs are activated by diverse intracellular signals through dissociation of inhibitors, by recruitment to transmembrane receptors (causing oligomerization and autophosphorylation), and through trans -phosphorylation by other kinases (Fig. 1) . TK signaling is terminated in part through the action of tyrosine phosphatases that hydrolyze tyrosyl phosphates and by the induction of inhibitory molecules.
mechanisms of tk dysregulation in cancer
Given the multiple levels of regulation of TKs, it is not surprising that TKs are dysregulated in cancer cells in several ways (Fig. 2) . A common mechanism of TK activation in hematologic cancers is the fusion of a receptor or nonreceptor TK with a partner protein, usually as a consequence of a balanced chromosomal translocation. A frequent feature of the partner protein is a domain that causes constitutive oligomerization of the TK in the absence of ligand binding or physiologic activating signals, thereby promoting autophosphorylation and activation. A primary example of this mechanism is BCR-ABL, the nonreceptor fusion TK in CML, in which a tetramerization domain in BCR overcomes autoinhibition of ABL catalytic activity through oligomerization and autophosphorylation. 4 With some receptor TKs, absence of the juxtamembrane inhibitory domain in the fusion protein contributes to activation.
A second important mechanism of TK dysregulation is a mutation that disrupts autoregulation of the kinase. Mutations in the Fms-like tyrosine kinase 3 (FLT3) receptor in acute myeloid leukemia (AML) render this TK active in the absence of ligand 5 ; in another example, small deletions and point mutations in the kinase domain of epidermal growth factor receptor (EGFR) in a subset of nonsmall-cell lung cancers increase the sensitivity of the receptor to its ligand 6 and alter receptor signaling. 7, 8 A third mechanism of TK dysregulation is increased or aberrant expression of a receptor TK, its ligand, or both. Examples include overexpression of the receptor TK ERBB2 (HER-2/neu) in breast cancer and overexpression of a mutant form of platelet-derived growth factor (PDGF), a receptor TK ligand, in dermatofibrosarcoma protuberans with t (11;17) . Lastly, increased TK activity can result from a decrease in factors that limit TK activity, such as impaired tyrosine phosphatase activity or decreased expression of TK inhibitor proteins. 9 Aberrant TK activation can increase the survival, proliferation, and cytotoxic drug resistance of malignant cells, and in tumors it can increase angiogenesis, invasiveness, and metastatic potential.
strategies to target tk s in cancer therapy
TKs can be inhibited pharmacologically through multiple mechanisms (Fig. 2) . The idea behind much of anti-TK drug discovery is to find small molecules that directly inhibit the catalytic activity of the kinase by interfering with the binding of ATP or substrates. Other anti-TK drugs may inhibit activation of fusion TKs by blocking their dimerization. Antibodies against receptor TKs or their ligands interrupt TK signaling through neutralization of ligand, blockade of ligand binding, receptor internalization, and perhaps antibody-mediated cytotoxicity. The stability of some TKs is regulated by binding to heat-shock proteins (e.g., heat-shock protein 90 [Hsp90]), and inhibitors of Hsp90 can disrupt the binding of client proteins such as BCR-ABL and HER-2, causing their degradation. An important advantage of TK-directed therapy is that it is possible to perform pharmacodynamic studies that correlate inhibition of the targeted TK in cancer cells with clinical responses to the drug. The prime example of a dysregulated TK in the hematologic cancers (Table 1) is BCR-ABL, which has been implicated as the direct cause of CML. 41 Imatinib mesylate (Gleevec), a 2-phenylaminopyrimidine compound that is a specific inhibitor of several TKs -namely, ABL, ABL-related gene product (ARG), c-KIT, and PDGF receptor (PDGFR) -induces complete hematologic and cytogenetic remissions in most patients with chronic-phase CML 10 but is much less effective in the accelerated and blast-crisis phases of the disease. 11 ABL is also activated by fusion to nucleoporin 214 (NUP214) in 5 percent of T-cell acute lymphoblastic leukemias 15 and to ETV6 (also known as TEL) in rare cases of atypical CML and acute leukemia, 13 both potential targets for imatinib. 14 Imatinib should also have activity in cancers caused by activated PDGFRs and c-KIT. PDGFR a is activated by cryptic interstitial chromosome 4 deletions that generate a FIP1L1-PDGFR a fusion TK in some patients with hypereosinophilic tks as targets in the treatment of malignant hematologic disorders , which induces oligomerization of the receptor and intermolecular phosphorylation (P, in yellow) of the activation-loop tyrosine. This leads to a conformational change in the catalytic domain and increased enzymatic activity, while phosphorylation of other tyrosines within the intracellular domain of the receptor creates binding sites for SH2 domain-containing signaling proteins, including c-SRC (red oval) and phospholipase C g (PLC g ) (green oval). c-ABL is activated through the phosphorylation of two regulatory tyrosines, one in the activation loop and the other near the SH3 binding site, which can be phosphorylated by another TK, such as c-SRC. In addition, activated PLC g can hydrolyze and destroy the lipid inhibitor PIP 2 . Further detail is provided in the review by Van Etten. 1 syndrome 27 or systemic mastocytosis, 29 whereas PDGFR b is activated in some patients with chronic myelomonocytic leukemia and balanced translocations that lead to fusion of PDGFR b with one of several partner proteins 31 (Table 1) . Imatinib induces dramatic clinical and molecular responses in both diseases. 32, 42 c-KIT is activated by point mutations in many cases of systemic mastocytosis or mast-cell leukemia and less frequently in AML. The most common c-KIT mutation involves D816 in the activation loop of the kinase domain, but this mutant is not inhibited by imatinib. 43 The normal c-KIT receptor is expressed on most AML blasts and may be overexpressed and activated in some patients, but the responses of AML to imatinib are variable and do not correlate well with inhibition of KIT signaling. 44 flt3: a major tk target in aml FLT3 is a receptor TK expressed on blasts in most cases of AML, and it is activated by duplications within the juxtamembrane domain 5 in 25 to 30 percent of patients and point mutations 21 at D835 in 5 to 7 percent of patients (Table 1) . Several inhibitors of FLT3 kinase activity are in various stages of development. 45 They inhibit growth and induce apoptosis in hematopoietic cell lines expressing activated FLT3 and have therapeutic efficacy in murine models of FLT3-induced leukemia. 46 In preliminary clinical trials, the drugs had few adverse effects and reduced circulating and bone marrow blasts in 20 to 50 percent of patients with relapsed or refractory AML. 22-24 Whether FLT3 inhibitors will benefit patients with AML whose blasts overexpress the normal FLT3 receptor is unclear. Such patients often do not have a response to FLT3 inhibitors, even though an autocrine FLT3 loop promotes the survival and growth of some AML blasts in vitro. 47, 48 other tk targets in malignant hematologic disorders
Other TKs have been implicated in hematologic cancers, but targeted therapeutics for these diseases are in their infancy. Fusion of the fibroblast growth factor receptor 1 (FGFR1) TK with one of several partners occurs in the 8p11 myeloproliferative syndrome, 18 and FGFR3 is mutated and overexpressed in multiple myeloma with t (4;14) . 20 Translocations involving the anaplastic lymphoma kinase ( ALK ) gene are pathognomonic of anaplastic large-cell lymphoma and generate fusion of the ALK receptor TK with several partners. 16 Fusion of Janus kinase 2 (JAK2), a nonreceptor TK, with TEL or BCR has been described in cases of acute leukemia and atypical CML, 36 whereas an activating point mutation (V617F) in JAK2 is found in the majority of patients with polycythemia vera and in some patients with essential thrombocytosis and idiopathic myelofibrosis. 34, 35 Preclinical studies suggest that many of these mutant TKs contribute to the pathogenesis of the disease. The excellent responses of chronic-phase CML and related syndromes to kinase-inhibitor therapy suggest that a dysregulated TK is the sole or predominant somatic genetic abnormality in the malignant cells. In contrast, one or more additional genetic abnormalities are required for the development of AML, 49 which may explain why the activity of FLT3 inhibitors in that disease is only moderate. FLT3 mutations may be acquired late in the evolution of some cases of AML and therefore in some cases are not central to the origins of the disease. 50 The extreme sensitivity of some cancers to TK inhibition may reflect their absolute dependence on the targeted TK-signaling pathway for survival. This phenomenon of "oncogene addiction" 51 can be seen when imatinib suppresses myeloid colony formation in Philadelphia chromo- some-positive bone marrow without affecting colonies from normal progenitors. 52 The responsiveness of some hematologic cancers to kinase-inhibitor therapy may also be due to simultaneous inhibition of more than one TK target. Imatinib inhibits both BCR-ABL and c-KIT in hematopoietic progenitors, and this dual activity may in part account for its efficacy in CML. 53 Similarly, the drug SU5416 inhibits vascular endothelial growth factor receptors (VEGFR) in addition to FLT3 and c-KIT; among patients with c-KIT-positive AML, those who had a response to SU5416 had increased VEGF levels before treatment and decreased bone marrow microvasculature after treatment. 24 The response to this drug may thus be mediated both by inhibition of c-KIT signaling in the blasts and by blockade of VEGFR activation in the bone marrow microenvironment.
imatinib targets in solid tumors: gist and beyond
Considerable evidence points to the involvement of TKs in a variety of solid tumors (Table 2 ). Most gastrointestinal stromal tumors (GISTs) carry mutations in c-KIT that are associated with constitutive activation and receptor phosphorylation. 65, 66 GISTs develop at high frequency in adults with germ-line KIT mutations, suggesting that c-KIT activation is insufficient for tumorigenesis. 91 Most patients with a GIST who do not have KIT mutations have mutations in PDGFR a . 85 Trials of imatinib in GIST that were prompted by these findings demonstrated partial responses in more than half the patients 67 ; those with KIT mutations in exon 11 had the best response, whereas the few patients without either KIT or PDGFR a mutations did not have a response. 92 In contrast to patients with chronicphase CML, complete responses to imatinib have not been observed in patients with GISTs, 67 and the varying responses of patients with different c-KIT mutations contrasts with the uniform in vitro sensitivity of these mutant receptors to the drug. Therefore, the dependence of GISTs on c-KIT signaling for survival and proliferation is probably incomplete and complex.
c-KIT and PDGFR have also been implicated in other solid tumors (Table 2) , although evidence of the efficacy of kinase inhibitors in these diseases is limited. There are activating kinase mutations in c-KIT in some testicular seminomas 68 and c-KIT mutations or overexpression 69 in small-cell lung cancer, but a phase 2 trial of imatinib in small-cell lung cancer yielded equivocal results. 70 Some glioblastoma cell lines simultaneously express PDGF and its receptors and display evidence of autocrine PDGFR signaling. 81 Imatinib inhibits the growth of these cells 83 and increases their sensitivity to ionizing radiation. 93 Imatinib is also active in dermatofibrosarcoma protuberans, 87 in which platelet-derived growth factor B is fused to collagen type I a 1 and overexpressed. 86 Finally, PDGFR a or PDGFR b is overexpressed in a subset of sarcomas 72, 82, 84 and chordomas, 94 some of which respond to imatinib (Table 2) .
small-molecule inhibitors of egfr
EGFR is overexpressed, mutated, or both in many solid tumors (Table 2) . 59 Gefitinib (Iressa) and ertks as targets for therapy of solid tumors In each case, the TKs known to be activated through that mechanism are listed. 55 whereas erlotinib yielded partial responses in 9 percent of similar patients and improved overall and progression-free survival in a phase 3 trial. 56 Disappointingly, the addition of gefitinib or erlotinib to chemotherapy in the initial treatment of non-small-cell lung cancer did not yield any additional benefit. 95, 96 A small subgroup of patients with non-smallcell lung cancer who frequently had adenocarcinomas and most of whom were Asian, female, and nonsmokers had dramatic and sometimes durable responses to gefitinib monotherapy. Sequencing of the EGFR gene in tumor tissue from these patients revealed somatic gain-of-function mutations clustered around the ATP-binding pocket of the kinase domain of the EGFR protein in most cases. 6, 7, 54 Unlike c-KIT mutations in GIST, these EGFR mutations do not cause constitutive activation; rather, they enhance the responsiveness of the receptor to EGF ligand and increase its sensitivity to inhibition by gefitinib 6,7 and may preferentially activate antiapoptotic signaling pathways in the tumor cells. 8 Paradoxically, in the Canadian randomized trial of erlotinib in non-small-cell lung cancer, tumorcell expression of EGFR was significantly corre- lated with the response to kinase inhibitor therapy, but EGFR mutational status was not. 97 In contrast, studies from Asia, where EGFR mutant tumors are more prevalent, have found significant increases in response rates and overall survival among patients with EGFR-mutant tumors treated with gefitinib. 98, 99 Additional prospective studies are needed to determine whether analysis of EGFR expression and mutation in tumors should be used to select patients with non-small-cell lung cancer for EGFRinhibitor therapy. EGFR kinase inhibitors are in phase 1 and 2 testing in a wide range of solid tumors. 100 EGFR is overexpressed in about 40 percent of glioblastomas and is activated by extracellular-domain deletions in a subset of these tumors, 57 but gefitinib had only minimal activity in a phase 2 trial in glioblastoma. 58
targeting receptor tks and their ligands with monoclonal antibodies
Receptor TK signaling can also be inhibited by monoclonal antibodies against the receptor or its ligand (Fig. 2) . The ERBB2 or HER-2 receptor TK is overexpressed through gene amplification in 20 to 25 percent of invasive primary and metastatic breast cancers and is associated with a poor prognosis. 61 Trastuzumab (Herceptin), a recombinant humanized monoclonal antibody against HER-2, increases response rates and improves survival when added to chemotherapy for metastatic HER-2-overexpressing breast cancer, 63 and in combination with adjuvant chemotherapy, it decreases recurrence in women who have early-stage breast cancer with HER-2 overexpression. 101 Another humanized monoclonal antibody, 2C4, blocks dimerization of HER-2 with other ErbB receptors and is in phase 1 studies. 102 HER-2 is mutated or overexpressed in other cancers, 62 which may also be candidates for anti-HER-2 therapy. A direct inhibitor of HER-2 kinase (CI-1033) is under development.
Several monoclonal antibodies against EGFR are also in development. Cetuximab (Erbitux) is a chimeric antibody against EGFR with activity in combination with chemotherapy in non-smallcell lung cancer, squamous-cell carcinoma of the * CML denotes chronic myeloid leukemia, ALL acute lymphoblastic leukemia, AML acute myeloid leukemia, aCML atypical chronic myeloid leukemia, T-ALL T-cell acute lymphoblastic leukemia, NPM nucleophosmin, ALCL anaplastic large-cell lymphoma, EMS 8p11 myeloproliferative syndrome, MM multiple myeloma, MDS myelodysplastic syndrome, HES hypereosinophilic syndrome, SM systemic mastocytosis, and CMML chronic myelomonocytic leukemia. † Chromosomal locations are given in parentheses. ‡ Other than imatinib, the drugs listed have not been approved by the Food and Drug Administration. § A therapeutic response is predicted on the basis of the identity of the tyrosine kinase but has not been verified clinically. The new england journal of medicine 180 head and neck, and colorectal cancer. In metastatic, EGFR-positive, chemotherapy-refractory colorectal cancer, cetuximab alone had minimal activity, but when combined with irinotecan it had a 22 percent response rate and modestly increased progression-free and overall survival, 60 leading to FDA approval for this indication in 2004. ABX-EGF is a humanized anti-EGFR monoclonal antibody with activity as a single agent in phase 2 trials in metastatic renal-cell and colorectal carcinoma. 103 Vascular endothelial growth factor (VEGF) is essential for angiogenesis, and either it or its two receptor TKs (VEGFR-1 and VEGFR-2) are overexpressed in many non-small-cell lung cancers and breast, prostate, renal-cell, and colorectal cancers. 104 A pivotal phase 3 study in metastatic co- The (Table 2) . Activating point mutations and fusions of the receptor TK RET occur in multiple endocrine neoplasia and radiation-associated thyroid cancer. 88 Similarly, the receptor TK MET is overexpressed in melanoma and musculoskeletal tumors, activated by point mutations in small-cell lung cancer and renal papillary carcinoma, and dysregulated by fusion with TPR in gastric carcinoma. The receptor TKs ROS, ALK, NTRK1, * IMT denotes inflammatory myofibroblastic tumor, NSCLC non-small-cell lung cancer, SSCHN squamous-cell carcinoma of head and neck, RCC renal-cell carcinoma, GIST gastrointestinal stromal tumor, SCLC small-cell lung cancer, PTC papillary thyroid carcinoma, PAIS pulmonary artery intimal sarcoma, DFSP dermatofibrosarcoma protuberans, COLIa1 collagen type Ia1, MEN-2A and MEN-2B multiple endocrine neoplasia types 2A and 2B, FMTC familial medullary thyroid carcinoma, and VEGF vascular endothelial growth factor. † Chromosomal locations are given in parentheses. ‡ Gefitinib, erlotinib, cetuximab, trastuzumab, imatinib, and bevacizumab have been approved by the Food and Drug Administration; the other drugs listed have not been approved. § A therapeutic response is predicted on the basis of the identity of the tyrosine kinase but has not been verified clinically. Targeted cancer therapies should be less toxic than conventional chemotherapy because they are specific for tumor cells. Consistent with this expectation, a maximum tolerated dose for imatinib was never reached in the phase 1 trials of this agent. However, some toxic effects of TK-targeted therapies may be related to inhibition of TKs in normal tissues and therefore difficult to eliminate. Defects in cell-mediated immunity have been reported in patients with imatinib-treated CML and may be a consequence of blockade of c-ABL signaling in T lymphocytes. 106 The cardiotoxicity of trastuzumab may reflect a requirement for HER-2 signaling in cardiomyocytes, whereas the acneiform rash frequently seen in patients who have a response to gefitinib and cetuximab may correlate with inhibition of EGFR signaling in skin.
Resistance to TK-targeted therapies is a growing problem and may be due to any of several mechanisms (Fig. 3) . Resistance to TK inhibitors was first identified in patients with advanced CML who had a relapse while receiving imatinib and was associated with point mutations that rendered the ABL kinase resistant to the drug or, less commonly, was associated with BCR-ABL gene amplification. 107 A long list of imatinib-resistant BCR-ABL mutants has been linked to drug resistance 108 and, in some cases, to disease progression. 109 Kinase mutations also play a role in acquired resistance to TK-inhibitor therapy in GIST and non-small-cell lung cancer. 110, 111 A proportion of the most primitive cancer stem cells or initiating cells, including quiescent Philadelphia chromosome-positive CD34+ cells in CML, 112 may be resistant to TK-targeted therapy -a finding that may account for the relatively low frequency of imatinib-induced molecular remissions in CML. 113 Mechanisms of resistance to monoclonal-antibody therapies targeting receptor TKs are poorly understood, but they are thought to include receptor down-regulation and loss of TK-inhibitory pathways. 114 Several strategies may prevent or overcome resistance to TK-targeted therapies. In CML, there are several second-generation ABL kinase inhibitors with increased potency and activity against most imatinib-resistant BCR-ABL mutants. 12 Drugs that irreversibly inactivate the kinase 115 or that block substrate binding 116 may overcome "gatekeeper" mutations (such as T315I in ABL), which cause resistance to all ATP-competitive inhibitors. Combinations of monoclonal antibodies against receptor TKs and small-molecule TK inhibitors of the receptor in solid tumors are under investigation. Another approach is to combine a TK inhibitor with cytotoxic chemotherapy or with drugs targeting other signaling pathways in the cancer cell. In colorectal cancer, cetuximab and bevacizumab show benefit only when combined with chemotherapy, but the mechanism is not understood. Finally, immune mechanisms may eradicate residual malignant disease, and trials of TK inhibitors in combination with adoptive immunotherapy or tumor-cell vaccines are warranted.
strategies to identify new tk targets in cancer
Constitutive activation of one or more TKs or downstream signaling pathways is likely in many if not most cancers, and we have only begun to identify them. Modern cytogenetics may be able to identify additional TKs activated through chromosomal translocations, rearrangements, and deletions in cancer cells. FISH analysis revealed ABL1 gene amplification in a subset of T-cell acute lymphoblastic leukemia 117 and led to the identification of the NUP214-ABL fusion protein. 15 In the hypereosinophilic syndrome and glioblastoma, activated fusion proteins involving the PDGFRa and ROS receptor TKs are generated through interstitial chromosomal deletions too small to be detected by routine cytogenetics, 27,89 but they might be revealed through array comparative genomic hybridization. A serendipitous approach, illustrated by the discovery of the FIP1L1-PDGFRa kinase in hypereosinophilic syndrome, 42 is to test each new TK inhibitor in a wide range of patients with cancer and to investigate the identity of the sensitive kinase in any patient who has a response. Flow-cytometric tech- niques to identify activated TKs and signaling pathways in primary cancer cells are showing promise. 118 Finally, a direct genomic approach can be pursued, where each exon of every TK is amplified by the polymerase chain reaction from tumor tissue and analyzed by DNA sequencing for potential activating mutations. This technique has identified several potential new activating TK mutations in colorectal cancer, 119 but it has a low yield. In cancers other than non-small-cell lung cancer, direct sequencing identified ERBB2 and EGFR mutations in only 3 of 303 primary tumors and none of 203 tumor cell lines. 6, 62 are changes in the drug-development process needed for tk-targeted therapies?
The future of TK-targeted therapeutics in cancer is promising, but some changes in our approach to the development of these drugs may be indicated. Therapeutic agents targeting TKs do not fit well into traditional phase 1, 2, or 3 drug-development programs because their toxicity profile can be low and because the therapeutic responses may be limited to a small subgroup of patients with a given cancer. 120 In phase 2 or 3 studies, patients should be selected on the basis of evidence of activation of the TK target in their tumors, and such studies should include pharmacodynamic analysis of target inhibition to avoid discarding a potentially valuable therapeutic agent because of perceived lack of efficacy. 121 The future of gefitinib is in jeopardy after a recent large phase 3 trial involving patients with refractory non-small-cell lung cancer showed that the drug conferred no survival benefit when compared with placebo 122 -a surprising finding, given that the expected frequency of tumors with responsive EGFR mutations was 8 to 10 percent and given that the study was powered to detect such differences. Patient stratification will lead to smaller potential markets for each newly approved TK-targeted cancer therapy, a situation that may discourage the drug-development process at a very early stage. Clinical development of imatinib was nearly abandoned because the market for a drug for CML was perceived to be too small, but the high prevalence of the disease and the durability of clinical responses have driven annual sales to more than $1 billion. However, the prevalence of the other hematologic cancers caused by activated TKs (Table 1) is far lower, and strategies to encourage the development of therapeutic agents targeting uncommon subtypes of cancer are needed.
Finally, some compromise among the pharmaceutical industry, government, and third-party payers will be necessary with respect to the expense of TK-targeted therapies, each of which is priced to generate annual revenues of $20,000 to $30,000 per patient. Limiting targeted therapies to patients identified by molecular profiling as those who may have a response would help control costs, but ultimately we may not be able to afford a pharmacy of such drugs, which often must be combined with other expensive treatments and which in some patients with cancer may offer only modest survival benefits.
